Concepts (272)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Milk, Human | 41 | 2022 | 164 | 12.890 |
Why?
|
| Infant, Very Low Birth Weight | 37 | 2022 | 165 | 9.280 |
Why?
|
| Intensive Care Units, Neonatal | 38 | 2022 | 185 | 7.590 |
Why?
|
| Breast Feeding | 30 | 2022 | 156 | 6.570 |
Why?
|
| Mothers | 22 | 2022 | 184 | 5.770 |
Why?
|
| Infant, Premature | 37 | 2021 | 187 | 5.080 |
Why?
|
| Infant, Newborn | 59 | 2022 | 637 | 4.600 |
Why?
|
| Enterocolitis, Necrotizing | 13 | 2022 | 33 | 3.200 |
Why?
|
| Lactation | 11 | 2021 | 63 | 2.560 |
Why?
|
| Infant | 26 | 2022 | 578 | 2.410 |
Why?
|
| Infant Nutritional Physiological Phenomena | 14 | 2021 | 63 | 2.390 |
Why?
|
| Milk Banks | 6 | 2020 | 22 | 2.200 |
Why?
|
| Patient Discharge | 8 | 2020 | 164 | 2.040 |
Why?
|
| Enteral Nutrition | 5 | 2022 | 56 | 1.820 |
Why?
|
| Infant, Premature, Diseases | 5 | 2020 | 26 | 1.810 |
Why?
|
| Child Development | 6 | 2020 | 71 | 1.560 |
Why?
|
| Infant Formula | 4 | 2020 | 22 | 1.460 |
Why?
|
| Intensive Care, Neonatal | 7 | 2020 | 35 | 1.360 |
Why?
|
| Female | 51 | 2022 | 17018 | 1.360 |
Why?
|
| Breast Milk Expression | 10 | 2020 | 41 | 1.270 |
Why?
|
| Humans | 65 | 2022 | 31070 | 1.230 |
Why?
|
| Social Support | 3 | 2019 | 194 | 1.210 |
Why?
|
| Gestational Age | 13 | 2020 | 78 | 1.090 |
Why?
|
| Residence Characteristics | 2 | 2019 | 226 | 1.070 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 335 | 0.920 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2020 | 17 | 0.870 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 86 | 0.850 |
Why?
|
| Health Care Costs | 4 | 2020 | 72 | 0.840 |
Why?
|
| Prospective Studies | 14 | 2021 | 1898 | 0.830 |
Why?
|
| Goals | 3 | 2017 | 45 | 0.810 |
Why?
|
| Bronchopulmonary Dysplasia | 3 | 2016 | 14 | 0.760 |
Why?
|
| Vitamin D | 1 | 2021 | 42 | 0.750 |
Why?
|
| Infant, Low Birth Weight | 2 | 2019 | 16 | 0.740 |
Why?
|
| Neonatology | 1 | 2020 | 3 | 0.730 |
Why?
|
| Birth Weight | 7 | 2022 | 35 | 0.720 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 32 | 0.710 |
Why?
|
| Gastroschisis | 1 | 2020 | 3 | 0.700 |
Why?
|
| Infant Care | 3 | 2016 | 17 | 0.680 |
Why?
|
| Child of Impaired Parents | 1 | 2019 | 11 | 0.680 |
Why?
|
| Diet | 3 | 2022 | 194 | 0.670 |
Why?
|
| Male | 31 | 2021 | 16499 | 0.660 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 55 | 0.650 |
Why?
|
| Aftercare | 1 | 2018 | 23 | 0.630 |
Why?
|
| Retrospective Studies | 12 | 2021 | 3665 | 0.630 |
Why?
|
| Anxiety | 1 | 2019 | 156 | 0.620 |
Why?
|
| Hospitalization | 4 | 2018 | 336 | 0.600 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2017 | 190 | 0.590 |
Why?
|
| Oxidative Stress | 1 | 2018 | 134 | 0.590 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 80 | 0.590 |
Why?
|
| Nervous System | 1 | 2017 | 10 | 0.590 |
Why?
|
| Maternal Behavior | 1 | 2017 | 14 | 0.580 |
Why?
|
| Pregnancy in Adolescence | 1 | 2017 | 13 | 0.570 |
Why?
|
| Stress, Psychological | 1 | 2019 | 254 | 0.560 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 199 | 0.560 |
Why?
|
| Educational Status | 5 | 2019 | 312 | 0.540 |
Why?
|
| Pregnancy | 4 | 2019 | 405 | 0.530 |
Why?
|
| Informed Consent | 1 | 2015 | 22 | 0.520 |
Why?
|
| Quality of Health Care | 1 | 2017 | 146 | 0.520 |
Why?
|
| United States | 6 | 2020 | 2375 | 0.510 |
Why?
|
| Quality Improvement | 1 | 2017 | 165 | 0.510 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 60 | 0.510 |
Why?
|
| Bacteria | 1 | 2016 | 89 | 0.510 |
Why?
|
| Mother-Child Relations | 1 | 2015 | 38 | 0.500 |
Why?
|
| Sepsis | 2 | 2017 | 154 | 0.500 |
Why?
|
| Depression | 1 | 2019 | 481 | 0.500 |
Why?
|
| Adult | 13 | 2020 | 8949 | 0.460 |
Why?
|
| Decision Making | 1 | 2015 | 237 | 0.440 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2016 | 211 | 0.430 |
Why?
|
| Oxygen | 2 | 2003 | 87 | 0.400 |
Why?
|
| Postpartum Period | 3 | 2021 | 26 | 0.390 |
Why?
|
| Nutritive Value | 2 | 2020 | 20 | 0.330 |
Why?
|
| Sleep | 2 | 2003 | 322 | 0.330 |
Why?
|
| Nutritional Status | 2 | 2020 | 46 | 0.330 |
Why?
|
| Infant, Extremely Low Birth Weight | 3 | 2017 | 21 | 0.320 |
Why?
|
| Models, Biological | 2 | 2009 | 346 | 0.300 |
Why?
|
| Cohort Studies | 8 | 2022 | 2045 | 0.280 |
Why?
|
| Child Language | 2 | 2017 | 11 | 0.280 |
Why?
|
| Incidence | 7 | 2020 | 790 | 0.270 |
Why?
|
| Age Factors | 2 | 2020 | 874 | 0.270 |
Why?
|
| Qualitative Research | 2 | 2017 | 118 | 0.260 |
Why?
|
| Infant, Extremely Premature | 2 | 2022 | 11 | 0.260 |
Why?
|
| Bottle Feeding | 2 | 2016 | 14 | 0.260 |
Why?
|
| Anthropometry | 1 | 2005 | 39 | 0.260 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 420 | 0.260 |
Why?
|
| Bedding and Linens | 2 | 2003 | 4 | 0.250 |
Why?
|
| Carbon Dioxide | 2 | 2003 | 20 | 0.250 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2017 | 318 | 0.240 |
Why?
|
| Child | 5 | 2022 | 1431 | 0.230 |
Why?
|
| Motor Activity | 2 | 2017 | 370 | 0.220 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1505 | 0.220 |
Why?
|
| Risk Factors | 4 | 2017 | 2593 | 0.220 |
Why?
|
| Prone Position | 1 | 2003 | 33 | 0.210 |
Why?
|
| Tissue Donors | 2 | 2021 | 81 | 0.210 |
Why?
|
| Risk | 2 | 2020 | 223 | 0.210 |
Why?
|
| Maternal Age | 2 | 2019 | 14 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 149 | 0.200 |
Why?
|
| Evidence-Based Practice | 3 | 2017 | 77 | 0.200 |
Why?
|
| Respiration | 1 | 2001 | 35 | 0.200 |
Why?
|
| Young Adult | 5 | 2019 | 2063 | 0.190 |
Why?
|
| Docosahexaenoic Acids | 1 | 2021 | 8 | 0.190 |
Why?
|
| Arachidonic Acid | 1 | 2021 | 14 | 0.190 |
Why?
|
| Directive Counseling | 2 | 2019 | 14 | 0.190 |
Why?
|
| Dietary Supplements | 1 | 2021 | 63 | 0.180 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2020 | 19 | 0.180 |
Why?
|
| Health Expenditures | 1 | 2020 | 20 | 0.180 |
Why?
|
| Premature Birth | 1 | 2020 | 11 | 0.180 |
Why?
|
| Tissue and Organ Procurement | 2 | 2017 | 35 | 0.180 |
Why?
|
| Time Factors | 3 | 2018 | 1681 | 0.180 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 156 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 360 | 0.170 |
Why?
|
| Health Status Disparities | 1 | 2020 | 74 | 0.170 |
Why?
|
| Linear Models | 2 | 2017 | 273 | 0.170 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 109 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 344 | 0.170 |
Why?
|
| Contraception Behavior | 1 | 2019 | 5 | 0.170 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 344 | 0.170 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 216 | 0.160 |
Why?
|
| Logistic Models | 2 | 2017 | 410 | 0.160 |
Why?
|
| Nutritional Support | 1 | 2018 | 23 | 0.160 |
Why?
|
| Social Class | 1 | 2019 | 70 | 0.160 |
Why?
|
| Food, Fortified | 1 | 2018 | 5 | 0.160 |
Why?
|
| F2-Isoprostanes | 1 | 2018 | 5 | 0.160 |
Why?
|
| Chicago | 3 | 2016 | 943 | 0.160 |
Why?
|
| Energy Intake | 1 | 2018 | 73 | 0.150 |
Why?
|
| Cognition | 2 | 2017 | 1427 | 0.150 |
Why?
|
| Length of Stay | 1 | 2020 | 339 | 0.150 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1008 | 0.150 |
Why?
|
| Nod1 Signaling Adaptor Protein | 1 | 2017 | 1 | 0.150 |
Why?
|
| Histamine H2 Antagonists | 1 | 2017 | 7 | 0.150 |
Why?
|
| Protective Factors | 1 | 2017 | 20 | 0.150 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2017 | 58 | 0.140 |
Why?
|
| Oligosaccharides | 1 | 2017 | 25 | 0.140 |
Why?
|
| Probiotics | 1 | 2017 | 21 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2017 | 65 | 0.140 |
Why?
|
| Peer Group | 1 | 2017 | 42 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1935 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 44 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2017 | 136 | 0.140 |
Why?
|
| Bacteremia | 1 | 2017 | 119 | 0.140 |
Why?
|
| Return to Work | 1 | 2016 | 53 | 0.130 |
Why?
|
| Anemia | 1 | 2017 | 100 | 0.130 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 53 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 44 | 0.130 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 64 | 0.130 |
Why?
|
| Phylogeny | 1 | 2016 | 69 | 0.130 |
Why?
|
| Illinois | 1 | 2016 | 267 | 0.130 |
Why?
|
| Cost of Illness | 2 | 2013 | 56 | 0.130 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 2015 | 6 | 0.130 |
Why?
|
| Feces | 1 | 2016 | 117 | 0.130 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2015 | 14 | 0.130 |
Why?
|
| Interviews as Topic | 1 | 2015 | 132 | 0.130 |
Why?
|
| Cost Savings | 1 | 2015 | 34 | 0.120 |
Why?
|
| Adolescent | 3 | 2017 | 2403 | 0.120 |
Why?
|
| Retinopathy of Prematurity | 1 | 2014 | 5 | 0.120 |
Why?
|
| Enterovirus Infections | 1 | 2013 | 1 | 0.110 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2013 | 2 | 0.110 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2013 | 3 | 0.110 |
Why?
|
| Meningoencephalitis | 1 | 2013 | 6 | 0.110 |
Why?
|
| Postnatal Care | 1 | 2013 | 7 | 0.110 |
Why?
|
| Feeding Methods | 1 | 2013 | 4 | 0.110 |
Why?
|
| Pharmacopoeias as Topic | 1 | 2012 | 3 | 0.110 |
Why?
|
| Propensity Score | 1 | 2013 | 36 | 0.110 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 37 | 0.110 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2003 | 7 | 0.100 |
Why?
|
| Direct Service Costs | 1 | 2012 | 4 | 0.100 |
Why?
|
| Tidal Volume | 2 | 2003 | 11 | 0.100 |
Why?
|
| Hospital Costs | 1 | 2013 | 69 | 0.100 |
Why?
|
| Cardiovascular Agents | 1 | 2012 | 32 | 0.100 |
Why?
|
| Sudden Infant Death | 2 | 2003 | 30 | 0.100 |
Why?
|
| Pediatrics | 1 | 2012 | 36 | 0.100 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2011 | 1 | 0.100 |
Why?
|
| Codon, Terminator | 1 | 2011 | 2 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2012 | 77 | 0.100 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 1 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2020 | 663 | 0.090 |
Why?
|
| Fluconazole | 1 | 2010 | 7 | 0.090 |
Why?
|
| Cultured Milk Products | 1 | 2009 | 2 | 0.090 |
Why?
|
| Mycoses | 1 | 2010 | 24 | 0.090 |
Why?
|
| Milk | 1 | 2009 | 12 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2010 | 39 | 0.090 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2010 | 39 | 0.090 |
Why?
|
| Animals | 5 | 2020 | 4724 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2018 | 429 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 551 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 464 | 0.070 |
Why?
|
| Ventricular Pressure | 1 | 1996 | 3 | 0.070 |
Why?
|
| Lidocaine | 1 | 1996 | 44 | 0.070 |
Why?
|
| Biomarkers | 2 | 2020 | 733 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2005 | 94 | 0.060 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1996 | 117 | 0.060 |
Why?
|
| Ion Channel Gating | 1 | 1996 | 185 | 0.060 |
Why?
|
| Blood Gas Analysis | 1 | 2003 | 9 | 0.050 |
Why?
|
| Respiratory Mechanics | 1 | 2003 | 9 | 0.050 |
Why?
|
| Videotape Recording | 1 | 2003 | 38 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 33 | 0.050 |
Why?
|
| Polysomnography | 1 | 2003 | 99 | 0.050 |
Why?
|
| Face | 1 | 2003 | 23 | 0.050 |
Why?
|
| Air | 1 | 2001 | 6 | 0.050 |
Why?
|
| Methods | 1 | 2001 | 17 | 0.050 |
Why?
|
| Environment | 1 | 2001 | 47 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2001 | 19 | 0.050 |
Why?
|
| Ranibizumab | 1 | 2020 | 2 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2020 | 4 | 0.050 |
Why?
|
| Choroid Diseases | 1 | 2020 | 3 | 0.050 |
Why?
|
| Intravitreal Injections | 1 | 2020 | 10 | 0.050 |
Why?
|
| Retinal Diseases | 1 | 2020 | 9 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 31 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2020 | 30 | 0.050 |
Why?
|
| Organ Transplantation | 1 | 2001 | 39 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 81 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 138 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 499 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2001 | 135 | 0.040 |
Why?
|
| Intention | 1 | 2019 | 28 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 453 | 0.040 |
Why?
|
| Oceania | 1 | 2018 | 2 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 10 | 0.040 |
Why?
|
| Africa | 1 | 2018 | 9 | 0.040 |
Why?
|
| North America | 1 | 2018 | 39 | 0.040 |
Why?
|
| North Carolina | 1 | 2018 | 5 | 0.040 |
Why?
|
| Obesity | 1 | 2021 | 307 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 25 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 80 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 354 | 0.040 |
Why?
|
| Weight Gain | 1 | 2018 | 70 | 0.040 |
Why?
|
| Income | 1 | 2018 | 80 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2017 | 73 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 148 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2017 | 293 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2013 | 691 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 379 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2016 | 80 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2015 | 13 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 25 | 0.030 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2015 | 29 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2015 | 110 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 254 | 0.030 |
Why?
|
| Cell Line | 1 | 2015 | 305 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 103 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2001 | 997 | 0.030 |
Why?
|
| Morbidity | 1 | 2014 | 65 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 718 | 0.030 |
Why?
|
| Enterovirus B, Human | 1 | 2013 | 1 | 0.030 |
Why?
|
| Ampicillin | 1 | 2013 | 7 | 0.030 |
Why?
|
| Gentamicins | 1 | 2013 | 16 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 232 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2013 | 19 | 0.030 |
Why?
|
| Inflammation | 1 | 2015 | 362 | 0.030 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2011 | 1 | 0.020 |
Why?
|
| Cardiology | 1 | 2012 | 75 | 0.020 |
Why?
|
| Disease Management | 1 | 2012 | 126 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 161 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 155 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2011 | 112 | 0.020 |
Why?
|
| Heterozygote | 1 | 2011 | 107 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2011 | 29 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 1683 | 0.020 |
Why?
|
| Cholestasis | 1 | 2010 | 8 | 0.020 |
Why?
|
| Colostrum | 1 | 2010 | 5 | 0.020 |
Why?
|
| Candidiasis | 1 | 2010 | 19 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2011 | 498 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1133 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 924 | 0.020 |
Why?
|
| Chick Embryo | 1 | 1996 | 20 | 0.020 |
Why?
|
| Isotonic Solutions | 1 | 1996 | 11 | 0.020 |
Why?
|
| Sodium Channels | 1 | 1996 | 16 | 0.020 |
Why?
|
| Verapamil | 1 | 1996 | 38 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 1996 | 39 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2010 | 3809 | 0.010 |
Why?
|
| Lymphoma | 1 | 2001 | 46 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 246 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2001 | 260 | 0.010 |
Why?
|